[1]黄阳,陈静波,林贵山.动态监测循环肿瘤细胞对寡转移非小细胞肺癌联合治疗预后的价值[J].福建医药杂志,2023,45(05):8-12.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(05):8-12.
点击复制

动态监测循环肿瘤细胞对寡转移非小细胞肺癌联合治疗预后的价值()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期数:
2023年05期
页码:
8-12
栏目:
临床研究
出版日期:
2023-10-15

文章信息/Info

Title:
Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer
文章编号:
1002-2600(2023)05-0008-05
作者:
黄阳; 陈静波; 林贵山1
福建省立医院肿瘤内科(福州 350001)
Author(s):
HUANG Yang;  CHEN Jingbo;  LIN Guishan
Department of Medical oncology, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, China
关键词:
非小细胞肺癌;  寡转移;  循环肿瘤细胞;  预后
Keywords:
non-small cell lung cancer;  oligometastases;  circulating tumor cells;  prognosis
分类号:
R734.2
文献标志码:
B
摘要:
目的 探讨动态监测循环肿瘤细胞(CTC)在预测寡转移非小细胞肺癌(NSCLC)患者全身治疗及局部放射治疗预后的潜在应用价值。方法 2019年1月至2020年12月确诊为无EGFR、ALK和ROS1突变的寡转移NSCLC患者52例,经全身治疗后,40例影像学评估为部分缓解或疾病稳定的患者纳入研究。所有患者接受帕博利珠单抗维持治疗,其中20例(50.0%)还接受所有转移病灶的放射治疗。收集所有患者维持治疗前、治疗后12个月的CTC及其生存资料。据患者维持治疗前至治疗后12个月CTC值的变化,将40例患者分为CTC下降组、稳定组和上升组,进行生存分析。结果 Kaplan-Meier生存分析显示,CTC不同变化组中位无进展生存期(PFS)分别为30.86、23.80、17.49个月(χ2=8.616,P=0.013)。CTC不同变化组中位总生存期分别为32.23、26.64、19.66个月(χ2=10.809, P=0.004)。在单因素及多因素Cox回归中,对转移灶进行放疗(HR=1.863,95%CI:1.263,2.749,P=0.002)、不同CTC变化(HR=2.562,95%CI:1.452,4.522,P=0.001)为PFS的独立预后因素。结论 动态监测CTC可以预测无EGFR、ALK、ROS1突变的寡转移NSCLC患者联合治疗的预后,具有一定的临床应用价值。
Abstract:
Objective To investigate the potential application value of dynamic monitoring of circulating tumor cell(CTC)in predicting the prognosis of systemic treatment and local radiotherapy in patients with oligometastatic non-small cell lung cancer(NSCLC).Methods From January 2019 to December 2020, 52 patients diagnosed with oligometastatic NSCLC without EGFR, ALK, and ROS1 mutations were included in the study.After systemic treatment, 40 patients with partial response or stable disease evaluated by imaging examination were included in the study.All patients received Pembrolizumab maintenance treatment, of which 20 patients(50.0%)also received radiotherapy for all metastasis.Collect CTC values of all patients before and 12 months after maintenance treatment and survival data.According to the changes in CTC values between before and 12 months after maintenance treatment, 40 patients were divided into a decreasing group(with a decrease in CTC count), a stable group(with no change in CTC count), and an increasing group(with an increase in CTC count)for survival analysis.Results Kaplan-Meier survival analysis showed that the median progress free survival(PFS)of different CTC change groups was 30.86, 23.80, and 17.49 months(χ2=8.616, P=0.013).The median overall survival(OS)of different groups of CTC change groups were 32.23, 26.64, and 19.66 months(χ2=10.809, P=0.004).The result of univariate and multivariate Cox regression revealed that radiotherapy for all metastatic lesions(HR=1.863,95%CI: 1.263,2.749, P=0.002)and different CTC changes(HR=2.562,95%CI: 1.452,4.522, P=0.001)were independent prognostic factors for PFS.Conclusion Dynamic monitoring of CTC can predict the prognosis of oligometastatic NSCLC patients without EGFR, ALK, or ROS1 mutations in combination therapy, and has certain clinical value.

参考文献/References:

[1] Hellman S,Weichselbaum R R.Oligometastases[J].J Clin Oncol, 1995, 13: 8-10.
[2] Mok T S K, Wu Y L, Kudaba I, et al.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet,2019,393(10183):1819-1830.
[3] Petrelli F, Ghidini A, Cabiddu M, et al.Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis[J]. Lung Cancer, 2018,126:194-200.
[4] Chiou V L, Burotto M.Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol,2015,33(31):3541-3543.
[5] Champiat S, Dercle L, Ammari S, et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1[J]. Clin Cancer Res,2017,23(8):1920-1928.
[6] Zhang J, Chen K, Fan Z H.Circulating Tumor Cell Isolation and Analysis[J]. Adv Clin Chem,2016,75(4):1-31.
[7] Krebs M G, Sloane R, Priest L, et al.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol,2011,29(12):1556-1563.
[8] Muinelo-Romay L, Vieito M, Abalo A, et al.Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-Line systemic treatment[J]. Cancers(Basel),2014,6(1):153-165.
[9] Juan O, Vidal J, Gisbert R, et al.Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine[J]. Clin Transl Oncol, 2014,16(7):637-643.
[10] Hirose T, Murata Y, Oki Y, et al.Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer[J]. Oncol Res, 2012,20(2-3):131-137.
[11] Wang J, Wang K, Xu J, et al.Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis[J]. PLoS One,2014,9(1):e78070.
[12] Dorsey J F, Kao G D, MacArthur K M, et al.Tracking viable circulating tumor cells(CTCs)in the peripheral blood of non-small cell lung cancer(NSCLC)patients undergoing definitive radiation therapy: pilot study results[J]. Cancer, 2015,121(1):139-149.
[13] Jianpeng L.Significance of circulating tumor cells in non-small-cell lung cancer patients: prognosis, chemotherapy efficacy, and survival[J]. J Healthc Eng,2021,11(9):2680526.
[14] Chen X, Wang X, He H, et al.Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer[J]. PLoS One, 2015,10(5):e0126276.

相似文献/References:

[1]林清华　吴联平　刘加夫　陈友轩　 齐春能　林玉琼　黄小红　郑　静.晚期非小细胞肺癌患者胸水液基细胞学蜡块中新抗体D5F3检测的临床价值[J].福建医药杂志,2019,41(01):3.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(05):3.
[2]陈新富 刘 宁 刘加夫.CK19在非小细胞肺癌淋巴结微转移中的检测价值(附90例分析)[J].福建医药杂志,2020,42(04):6.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(05):6.
[3]林 潇 陈愉生 李鸿茹.查尔森合并症指数及简化合并症评分对晚期非小细胞肺癌预后的影响[J].福建医药杂志,2020,42(05):23.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(05):23.
[4]李荣宾,黄延延,林贤宾,等.IGF1/RPI3K/Akt通路及其调控对非小细胞肺癌血管生成拟态形成影响的研究[J].福建医药杂志,2023,45(03):112.
[5]钟颖,邹立,陈声池.EGFR T790M突变丰度对阿美替尼治疗晚期非小细胞肺癌疗效的影响[J].福建医药杂志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(05):17.[doi:10.20148/j.fmj.2024.01.005]

备注/Memo

备注/Memo:
基金项目:福建省科技厅重点项目(2019Y0055)
1 通信作者,Email:lingsh70@163.com
更新日期/Last Update: 2023-10-15